Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts

Rebecca L. VanOosten, Jill M. Moore, Aaron T. Ludwig, Thomas S. Griffith

Research output: Contribution to journalArticlepeer-review

70 Scopus citations


TRAIL (TNF-related apoptosis-inducing ligand) induces apoptosis in various tumor cell types and is under investigation as a cancer therapeutic. The development of a recombinant adenovirus encoding the full-length human TRAIL gene (Ad5-TRAIL) replaces the need for large quantities of soluble TRAIL protein in tumor suppressive therapies. However, the full potential of Ad5-TRAIL has not yet been maximized. Recent investigation of a histone deacetylase inhibitor, depsipeptide (FR901228), has demonstrated that it increases cellular susceptibility to adenovirus infection and augments adenoviral transgene expression. Thus, studies were initiated to evaluate the ability of depsipeptide to enhance the cytotoxic activity of Ad5-TRAIL against human prostate tumor cells. In vitro, depsipeptide increased expression of coxsackie-adenovirus receptor, leading to increased adenoviral infection and transgene expression. Additionally, tumor cell killing by Ad5-TRAIL was higher following depsipeptide pretreatment. More surprisingly, depsipeptide also increased prostate tumor cell sensitivity to TRAIL-induced apoptosis. Investigation into the mechanism responsible for increased TRAIL responsiveness revealed increased levels of TRAIL-R1 and -R2 in membrane lipid rafts following depsipeptide treatment. These results indicate that depsipeptide is a potent agent for enhancing the activity of Ad5-TRAIL by multiple mechanisms, allowing for a more efficient use of Ad5-TRAIL as an antitumor therapy.

Original languageEnglish (US)
Pages (from-to)542-552
Number of pages11
JournalMolecular Therapy
Issue number4
StatePublished - Apr 2005

Bibliographical note

Funding Information:
The authors thank Drs. Bennett Elzey and Timothy Ratliff for careful reading of the manuscript. This work was supported by a Young Investigator Award from The Alliance for Cancer Gene Therapy and a Department of Defense Prostate Cancer Research Program New Investigator Award (PC010599).


  • Adenovirus
  • Apoptosis
  • Depsipeptide
  • Gene therapy
  • Lipid rafts
  • Tumor


Dive into the research topics of 'Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts'. Together they form a unique fingerprint.

Cite this